Skip to main content
. 2019 Dec;8(6):1000–1015. doi: 10.21037/tlcr.2019.12.08

Figure 5.

Figure 5

Clinicopathologic characteristics and methylation of ASC/TMS1/PYCARD CpG sites with significant impact on overall survival in patients with lung cancer: (A) N-stage; (B) TNM-stage; (C) ASC/TMS1/PYCARD CpG4 in non-malignant tissue; (D) ASC/TMS1 CpG4 in tumor tissue; (E) ASC/TMS1/PYCARD CpG7 in non-malignant tissue. Tick marks indicate censored cases.